Javier Bolaños Meade, MD
@GvHD_Meade
Followers
719
Following
6K
Media
85
Statuses
2K
Fan of Aquinas, Boethius and Lady Philosophy, Anselm (and Gaunilo), John Dunce Scotus, Petrarch, and transplant immunology. GvHD student. Opinions my own.
Joined May 2020
Enjoying @Amtrak train 141 to Norfolk "Business Class" car with no air conditioning. Sure it is an experience of a lifetime. Never again...
4
0
5
Arma fatalia, quae nunc in bellis adhibentur, ad maiorem nos ducere minantur feritatem quam antea. In nomine humanae dignitatis et iuris nationum, renovamus coram auctoribus quae Papa Franciscus dicebat: clades semper est bellum! Et iuxta verba Pii XII: «In pace nihil perditur,
8
52
467
Excited to share findings from the multicenter ACCESS trial, supported by @CIBMTR & @nmdp_org . PTCy-based GVHD prophylaxis improved survival after MMUD HCT. Grateful for this collaboration advancing equitable transplant access. #ADonorForAll
0
1
8
#PTCyRules As we published two years ago, MTX based prophylaxis is not SOC in RIC BMT anymore. Now the same can be said in myeloablative BMT. Well done @ALLGtrials
ALLG's BM12 CAST trial has shown game-changing results, changing 40 years of standard practice in GVHD prophylaxis for stem cell transplants. Presented at EHA2025 by Prof David Curtis & published in NEJM today, read more here: https://t.co/y5lnAn0Jj0
#clinicaltrials #EHA2025
2
4
21
Plenary #3 #EHA2025 Very proud 🇦🇺 of @ALLGtrials randomized CAST trial Practice-changing study showing substantial reduction in GRFS, relapse-free survival & GvHD for PTCy in matched sibling donor allogeneic transplant Out in @NEJM
https://t.co/N0mByVBzTg
#bmtsm
0
3
9
If @Stellantis survives their poor quality and the presidencial stupidity I will be in awe.
0
0
1
Join our IV @SBTMO meeting on prevention & treatment of relapse after HCT! 100% virtual! 🙏to the chairs, moderators & all speakers @GvHD_Meade @DrLornan @DrCCutler @MahadeoKris @End_myeloma @mbeksac56 @NicoGagelmann @hamer26004350 @AdrianaSeber1 @pagliuca_simona @lucila_kerbauy
We are excited to present all the confirmed speakers for our IV #MultiregionalSBTMO Meeting! 📅 March 21-22 | 100% online 🔗Register now: https://t.co/gBiSc0gGp6 Don't miss the opportunity to expand your knowledge, enhance your practice, and grow your professional network!
0
9
17
We are excited to present all the confirmed speakers for our IV #MultiregionalSBTMO Meeting! 📅 March 21-22 | 100% online 🔗Register now: https://t.co/gBiSc0gGp6 Don't miss the opportunity to expand your knowledge, enhance your practice, and grow your professional network!
0
2
6
Our first 2025 paper was published today in JITC Explores the "obesity paradox" in cancer immunotherapy: 1️⃣ Obese patients have better IO outcomes (despite ⬆️cancer risk) 2️⃣ Obesity → ⬆️T-cell exhaustion →⬆️ ICI benefit https://t.co/0VFM1YpFF3
18
51
243
My grandfather was (thankfully) rejected from the British Armed Forces during WWII when he wanted to join the fight against the Axis, a war that killed millions (The US Armed Forces lost 407,316 members). So no, I do not approve of what happened yesterday. Nazism is NOT ok.
1
0
2
"Panem et circenses" Decimus Iunius Iuvenalis... or was it TikTok?
1
1
3
This was, to me, a bit surprising. In any event my appendix left me in 1987! Appendicectomy versus antibiotics for acute uncomplicated appendicitis in children: an open-label, international, multicentre, randomised, non-inferiority trial - The Lancet
thelancet.com
Based on cumulative failure rates and a 20% non-inferiority margin, antibiotic management of non-perforated appendicitis was inferior to appendicectomy.
0
0
5
@MediHumdani @BMTCTN @sghmd @GvHD_Meade We would like to inform you that your post has been published on @Oncodaily. Thank you for sharing! https://t.co/0qZPGzHm0f
oncodaily.com
Mehdi Hamadani: Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide / Alison W. Loren, Ami S. Bhatt, Amin M. Alousi, Andrew R. Rezvani,
0
1
4